Many new drug candidates face the hurdle of low aqueous solubility, hindering their absorption and progression to clinical trials. PBPK modeling, coupled with strategic in vitro measurements, offers a rapid and cost-effective approach to identify potential absorption risks and select optimal drug forms and formulations
In this webinar,we will discuss the role of solid form screening and PBPK modeling to enable accelerated timelines desirable in early-phase drug development. Also, we will share formulation maps for amorphous solid dispersions (ASDs) and key criteria for salt screening that are used to select the right formulation in early-phase screening for enabled forms. Using a model drug case study, the optimized pathway to lead-enabled form selection using a combination of in-vitro characterization techniques and in-silico modeling tools is highlighted.;
Key Learning Objectives:
- Learn how PBPK modeling can identify potential oral absorption risks for early drug candidates
- Understand the importance of solid form screening and form selection in oral pharmaceutical development
- Learn how PBPK modeling coupled with in-vitro testing and solid form screening can guide the early selection of drug form and formulation to achieve pre-clinical and clinical study goals (e.g. bioavailability enhancement) for a model compound